Citizens JMP raised the firm’s price target on Astria Therapeutics (ATXS) to $26 from $25 and keeps an Outperform rating on the shares. Astria Therapeutics continues to execute on navenibart, with potentially derisking first-in- human data for STAR-0310 coming this quarter, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATXS:
- Strong Financial Position and Strategic Partnerships Drive Buy Rating for Astria Therapeutics
- Astria Therapeutics Reports Increased Losses Amid R&D Expansion
- Astria Therapeutics reports Q2 EPS (57c), consensus (58c)
- Astria Therapeutics expects cash to fund operations into 2028
- ATXS Earnings this Week: How Will it Perform?